Showing 3661-3670 of 7134 results for "".
- From EADV: Temtokibart Shows Sustained Efficacy in AD; New DELTA TEEN Datahttps://practicaldermatology.com/news/from-eadv-temtokibart-shows-sustained-efficacy-in-ad-new-delta-teen-data/2483428/LEO Pharma announced data from several important trials and presented updates on delgocitinib LEO Pharma presented phase 2b data for its investigational agent temtokibart (LEO 138559) at the 2025 European Academy of Dermatolo
- Analysis: IL-17, JAK Inhibitors May Carry Elevated Risk for TBhttps://practicaldermatology.com/news/analysis-il-17-jak-inhibitors-may-carry-elevated-risk-for-tb/2483387/A large population-based analysis using data from TriNetX suggests a elevated risk of active tuberculosis (TB) in patients treated with systemic immunosuppressive therapies (including IL-17, IL-23, IL-12/23, Janus kinase (JAK) inhibitors), cyclosporine, and tumor ne
- LEO To Focus on New Data for CHE, AD, and PsO at EADV 2025https://practicaldermatology.com/news/leo-to-present-data-on-che-ad-and-pso-at-eadv-2025/2483384/LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational a
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- HS TRUTHS Video Series Centers Patient Experiencehttps://practicaldermatology.com/news/hs-truths-video-series-centers-patient-experience/2483232/Incyte announced this week that it has launched HS TRUTHS, a new disease education initiative aiming to elevate awareness of the lived experiences of individuals with hidradenitis suppurativa (HS).
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Recall of DermaRite Industries Products Expandshttps://practicaldermatology.com/news/recall-of-dermarite-sanitizers-and-cleansers-expands/2483166/Citing an abundance of caution, DermaRite Industries has announced it is expanding its voluntary recall of hand sanitizers and cleansers initiated on